SANN is currently developing the following drugs: Vamorolone 40 Mg/Ml Oral Suspension, Midazolam, Vamorolone, Vamorolone, Eplerenone, Fludrocortisone. These drug candidates are in various stages of clinical development as the company works toward FDA approval.